Subverted macrophages in the triple-negative breast cancer ecosystem.

[1]  Huayao Li,et al.  Plant-derived nanoparticles and plant virus nanoparticles: Bioactivity, health management, and delivery potential. , 2023, Critical reviews in food science and nutrition.

[2]  Xuetao Cao,et al.  Glucose metabolism of TAMs in tumor chemoresistance and metastasis. , 2023, Trends in cell biology.

[3]  L. Akkari,et al.  Macrophages at the interface of the co-evolving cancer ecosystem , 2023, Cell.

[4]  Haotian Zhang,et al.  MARCO is a potential prognostic and immunotherapy biomarker. , 2023, International immunopharmacology.

[5]  A. Veillette,et al.  Improving treatment of solid cancers by nanoconjugate-mediated immune conversion of tumour cells. , 2022, Nature nanotechnology.

[6]  Jing Zhao,et al.  TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress , 2022, Frontiers in Oncology.

[7]  P. Allavena,et al.  Macrophages as tools and targets in cancer therapy , 2022, Nature Reviews Drug Discovery.

[8]  Q. Sun,et al.  The Prognostic and Clinical Value of Tumor-Associated Macrophages in Patients With Breast Cancer: A Systematic Review and Meta-Analysis , 2022, Frontiers in Oncology.

[9]  K. Ravichandran,et al.  Drugging the efferocytosis process: concepts and opportunities , 2022, Nature Reviews Drug Discovery.

[10]  Kumar Ganesan,et al.  Role of Biological Mediators of Tumor-Associated Macrophages in Breast Cancer Progression. , 2022, Current medicinal chemistry.

[11]  H. Augustin,et al.  Tie2 Receptor in Tumor-Infiltrating Macrophages Is Dispensable for Tumor Angiogenesis and Tumor Relapse after Chemotherapy , 2022, Cancer research.

[12]  C. Pan,et al.  CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy , 2022, Journal of experimental & clinical cancer research : CR.

[13]  Y. Zhu,et al.  Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer , 2022, Journal for ImmunoTherapy of Cancer.

[14]  F. Sendra-Portero,et al.  Factors and molecular mechanisms of radiation resistance in cancer cells , 2022, International journal of radiation biology.

[15]  I. Larionova,et al.  Radiotherapy resistance: identifying universal biomarkers for various human cancers , 2022, Journal of Cancer Research and Clinical Oncology.

[16]  Shumin Wang,et al.  Specific diagnosis of lymph node micrometastasis in breast cancer by targeting activatable near-infrared fluorescence imaging. , 2022, Biomaterials.

[17]  Zheng Gu,et al.  Leveraging Macrophages for Cancer Theranostics. , 2022, Advanced drug delivery reviews.

[18]  I. Baranowska-Bosiacka,et al.  CXCR2 Receptor: Regulation of Expression, Signal Transduction, and Involvement in Cancer , 2022, International journal of molecular sciences.

[19]  D. Davidson,et al.  Inflammatory macrophages exploit unconventional pro-phagocytic integrins for phagocytosis and anti-tumor immunity. , 2021, Cell reports.

[20]  Y. Zhan,et al.  Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds? , 2021, Frontiers in Immunology.

[21]  I. Baranowska-Bosiacka,et al.  Chronic and Cycling Hypoxia: Drivers of Cancer Chronic Inflammation through HIF-1 and NF-κB Activation: A Review of the Molecular Mechanisms , 2021, International journal of molecular sciences.

[22]  F. Martinon,et al.  Tumor-induced reshuffling of lipid composition on the ER membrane sustains macrophage survival and pro-tumorigenic activity , 2021, Nature Immunology.

[23]  A. Balkrishna,et al.  Unveiling Novel Therapeutic Drug Targets and Prognostic Markers of Triple Negative Breast Cancer. , 2021, Current cancer drug targets.

[24]  Qin Xu,et al.  Remodeling “cold” tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona , 2021, Acta pharmaceutica Sinica. B.

[25]  Lihua Luo,et al.  Dual Inhibition of Endoplasmic Reticulum Stress and Oxidation Stress Manipulates the Polarization of Macrophages under Hypoxia to Sensitize Immunotherapy. , 2021, ACS nano.

[26]  A. Devitt,et al.  Macrophages: The Good, the Bad, and the Gluttony , 2021, Frontiers in Immunology.

[27]  Amit A. Patel,et al.  Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. , 2021, Immunity.

[28]  Sherine F. Elsawa,et al.  Macrophage Polarization States in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[29]  L. Jia,et al.  M2-like tumour-associated macrophage-secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway , 2021, Molecular medicine reports.

[30]  J. Nam,et al.  Tumor microenvironment and radioresistance , 2021, Experimental & Molecular Medicine.

[31]  D. Chan,et al.  The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression , 2021, International journal of molecular sciences.

[32]  C. Rudin,et al.  Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. , 2021, Cancer cell.

[33]  A. Mackiewicz,et al.  Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance , 2021, Frontiers in Immunology.

[34]  Eric Ubil,et al.  Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes , 2021, Frontiers in Immunology.

[35]  Wei Wei,et al.  CAR-macrophage: A new immunotherapy candidate against solid tumors. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[36]  Xiaohan Zhang,et al.  A sweet spot for macrophages: focusing on polarization. , 2021, Pharmacological research.

[37]  Yuan Yin,et al.  Cancer-associated fibroblasts in gastric cancer affect malignant progression via the CXCL12-CXCR4 axis , 2021, Journal of Cancer.

[38]  Christine E. Brown,et al.  Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy , 2021, Frontiers in Immunology.

[39]  C. Hammer,et al.  Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion , 2021, Nature Reviews Cancer.

[40]  Pengyuan Yang,et al.  RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming , 2021, Nature Communications.

[41]  Jianguo Wang,et al.  Targeting tumor-associated macrophages to synergize tumor immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[42]  Xueda Hu,et al.  A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells , 2021, Cell.

[43]  P. Allavena,et al.  Tumor-associated myeloid cells: diversity and therapeutic targeting , 2021, Cellular & Molecular Immunology.

[44]  L. Xue,et al.  Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer , 2021, Journal for ImmunoTherapy of Cancer.

[45]  Guifeng Zhang,et al.  Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes , 2021, Theranostics.

[46]  Shengqi Wang,et al.  Research trends in pharmacological modulation of tumor‐associated macrophages , 2021, Clinical and translational medicine.

[47]  Pingping Shen,et al.  Targeting tumor-associated macrophages as an antitumor strategy. , 2020, Biochemical pharmacology.

[48]  Ting Zhang,et al.  Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.

[49]  F. Cheng,et al.  Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1β production , 2020, Cellular & Molecular Immunology.

[50]  Xuemei Ji,et al.  Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer , 2020, Cell Death & Disease.

[51]  I. Poon,et al.  Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis , 2020, JAMA network open.

[52]  S. Pinder,et al.  Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression , 2021, Science advances.

[53]  Qiong Zhou,et al.  Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy. , 2020, Pharmacological research.

[54]  Xiaoyuan Chen,et al.  Engineering Macrophages for Cancer Immunotherapy and Drug Delivery , 2020, Advanced materials.

[55]  Dakang Xu,et al.  Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment , 2020, Frontiers in Immunology.

[56]  Maxim N. Artyomov,et al.  TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy , 2020, Cell.

[57]  Xiaoyu Zhang,et al.  M2 macrophages contribute to cell proliferation and migration of breast cancer , 2020, Cell biology international.

[58]  M. Rosemann,et al.  Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC , 2020, Cancer Immunology, Immunotherapy.

[59]  I. Kwon,et al.  Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[60]  M. Villanueva.  Macrophages get a CAR , 2020, Nature Reviews Drug Discovery.

[61]  C. Weidong,et al.  Macrophage M1/M2 polarization. , 2020, European journal of pharmacology.

[62]  Martha E. Zeeman,et al.  Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.

[63]  X. Jia,et al.  CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis , 2020, Molecular Cancer.

[64]  Xikun Zhou,et al.  Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.

[65]  A. Mantovani,et al.  Diversity, Mechanisms, and Significance of Macrophage Plasticity. , 2020, Annual review of pathology.

[66]  W. ElShamy,et al.  The immunosuppressive microenvironment in BRCA1-IRIS-overexpressing TNBC tumors is induced by bidirectional interaction with tumor-associated macrophages. , 2020, Cancer research.

[67]  P. Allavena,et al.  Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses , 2019, Cells.

[68]  I. Tabas,et al.  Efferocytosis in health and disease , 2019, Nature Reviews Immunology.

[69]  Chung-Pei Li,et al.  miR-200c/PAI-2 promotes the progression of triple negative breast cancer via M1/M2 polarization induction of macrophage. , 2019, International immunopharmacology.

[70]  C. Jewell,et al.  Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy. , 2019, Current opinion in biotechnology.

[71]  C. Shao,et al.  Harnessing tumor-associated macrophages as aids for cancer immunotherapy , 2019, Molecular Cancer.

[72]  Y. Xi,et al.  Macrophage Colony-stimulating Factor Mediates the Recruitment of Macrophages in Triple negative Breast Cancer , 2019, International journal of biological sciences.

[73]  E. Izquierdo,et al.  Targeting Macrophages: Friends or Foes in Disease? , 2019, Front. Pharmacol..

[74]  Yibing Chen,et al.  Tumor-associated macrophages: an accomplice in solid tumor progression , 2019, Journal of Biomedical Science.

[75]  Betty Y. S. Kim,et al.  Phagocytosis checkpoints as new targets for cancer immunotherapy , 2019, Nature Reviews Cancer.

[76]  A. Ribas,et al.  Tumour-intrinsic resistance to immune checkpoint blockade , 2019, Nature Reviews Immunology.

[77]  R. Wilkinson,et al.  Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies , 2019, Journal of Immunotherapy for Cancer.

[78]  E. Holland,et al.  Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers , 2019, Nature Communications.

[79]  Shanchun Guo,et al.  Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. , 2019, Current medicinal chemistry.

[80]  Rachel E. Brewer,et al.  CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy , 2019, Nature.

[81]  Huiyin Lan,et al.  Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications , 2019, Journal of Hematology & Oncology.

[82]  Dong Wang,et al.  Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. , 2019, Cancer letters.

[83]  T. Fry,et al.  Mechanisms of resistance to CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[84]  K. Pienta,et al.  Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment , 2019, Molecular Cancer.

[85]  Maria Anna Rapsomaniki,et al.  A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer , 2019, Cell.

[86]  R. Cubas,et al.  Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. , 2019, Cancer research.

[87]  S. Miyano,et al.  Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance , 2019, The Journal of clinical investigation.

[88]  M. Harmsen,et al.  Reactive oxygen species (ROS) in macrophage activation and function in diabetes. , 2019, Immunobiology.

[89]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.

[90]  R. Jain,et al.  Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer , 2019, Proceedings of the National Academy of Sciences.

[91]  E. Deutsch,et al.  CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated with TNFα-Mediated Resistance , 2019, Cancer Immunology Research.

[92]  Yuquan Wei,et al.  Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[93]  Y. Carmi,et al.  Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation , 2018, Proceedings of the National Academy of Sciences.

[94]  Cui Tang,et al.  Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. , 2018, Biomaterials.

[95]  E. D. de Vries,et al.  Tumor-associated macrophages in breast cancer: Innocent bystander or important player? , 2018, Cancer treatment reviews.

[96]  Evan W. Newell,et al.  High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy , 2018, Cell.

[97]  J. Pollard,et al.  Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.

[98]  Sathish Kumar Mungamuri,et al.  Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity , 2018, The Journal of clinical investigation.

[99]  Yang Zhao,et al.  The origins and homeostasis of monocytes and tissue‐resident macrophages in physiological situation , 2018, Journal of cellular physiology.

[100]  Y. Morine,et al.  Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction , 2018, Cell Communication and Signaling.

[101]  J. T. Afshari,et al.  Macrophage plasticity, polarization, and function in health and disease , 2018, Journal of cellular physiology.

[102]  Benjamin P. C. Chen,et al.  LILRB4 signaling in leukemia cells mediates T cell suppression and tumor infiltration , 2018, Nature.

[103]  O. De Wever,et al.  Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer , 2018, Journal of Experimental & Clinical Cancer Research.

[104]  Ambrose J. Carr,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.

[105]  yang-xin fu,et al.  Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. , 2018, Cell reports.

[106]  K. Okkenhaug,et al.  Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. , 2018, JCI insight.

[107]  M. Tzardi,et al.  Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages , 2018, Cell Death & Disease.

[108]  Michael F. Cuccarese,et al.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy , 2018, Nature Biomedical Engineering.

[109]  M. Ernst,et al.  Targeting Macrophages in Cancer: From Bench to Bedside , 2018, Front. Oncol..

[110]  Y. Kienast,et al.  Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity , 2018, The Journal of experimental medicine.

[111]  S. Kaech,et al.  Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity , 2018, The Journal of experimental medicine.

[112]  A. Veillette,et al.  SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy. , 2018, Trends in immunology.

[113]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[114]  Junjeong Choi,et al.  The role of tumor-associated macrophage in breast cancer biology. , 2018, Histology and histopathology.

[115]  Zhiqiang Ma,et al.  Targeting Gas6/TAM in cancer cells and tumor microenvironment , 2018, Molecular Cancer.

[116]  Chaur-Dong Hsu,et al.  VEGF may contribute to macrophage recruitment and M2 polarization in the decidua , 2018, PloS one.

[117]  T. Iida,et al.  The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis , 2017, International journal of molecular sciences.

[118]  O. Larsson,et al.  Cancer as an ecomolecular disease and a neoplastic consortium. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[119]  P. Allavena,et al.  Targeting tumor associated macrophages: The new challenge for nanomedicine. , 2017, Seminars in immunology.

[120]  I. Weissman,et al.  Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity , 2017, Proceedings of the National Academy of Sciences.

[121]  M. Quigley,et al.  Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity , 2017, Cancer Immunology Research.

[122]  D. Mevorach,et al.  Apoptotic Cells Induced Signaling for Immune Homeostasis in Macrophages and Dendritic Cells , 2017, Front. Immunol..

[123]  G. Storm,et al.  Targeting the Stat6 pathway in tumor‐associated macrophages reduces tumor growth and metastatic niche formation in breast cancer , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[124]  M. Zaidi,et al.  TAMeless traitors: macrophages in cancer progression and metastasis , 2017, British Journal of Cancer.

[125]  R. Coffman,et al.  Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. , 2017, JCI insight.

[126]  J. Healey,et al.  HPMA–Copolymer Nanocarrier Targets Tumor-Associated Macrophages in Primary and Metastatic Breast Cancer , 2017, Molecular Cancer Therapeutics.

[127]  R. Satija,et al.  Single-cell RNA sequencing to explore immune cell heterogeneity , 2017, Nature Reviews Immunology.

[128]  C. Ries,et al.  Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy , 2017, Journal of Immunotherapy for Cancer.

[129]  W. Moon,et al.  Investigation of discriminant metabolites in tamoxifen-resistant and choline kinase-alpha-downregulated breast cancer cells using 1H-nuclear magnetic resonance spectroscopy , 2017, PloS one.

[130]  Ou Sha,et al.  Anti-tumor Activity of Toll-Like Receptor 7 Agonists , 2017, Front. Pharmacol..

[131]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[132]  J. Aerts,et al.  Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy , 2017, Cancer Immunology Research.

[133]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[134]  Heather H Gustafson,et al.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics. , 2017, Advanced drug delivery reviews.

[135]  Miles A. Miller,et al.  In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy , 2017, Science Translational Medicine.

[136]  K. Weiskopf.  Cancer immunotherapy targeting the CD47/SIRPα axis. , 2017, European journal of cancer.

[137]  J. Pollard,et al.  Repolarizing macrophages improves breast cancer therapy , 2017, Cell Research.

[138]  Emily A Foley,et al.  Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents , 2017, Cell reports.

[139]  Yuka Kanno,et al.  Mechanisms and consequences of Jak–STAT signaling in the immune system , 2017, Nature Immunology.

[140]  A. Letai,et al.  Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages , 2017, Nature.

[141]  S. Hanash,et al.  Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells , 2017, Cancer immunology research.

[142]  H. Okada,et al.  Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy , 2017, Oncogene.

[143]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[144]  L. Puskás,et al.  Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters , 2017, Mediators of inflammation.

[145]  A. V. Nguyen,et al.  Corrigendum: PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.

[146]  S. Trudel,et al.  TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding , 2016, Clinical Cancer Research.

[147]  J. Pollard,et al.  Inhibiting macrophage PI3Kγ to enhance immunotherapy , 2016, Cell Research.

[148]  J. Kutok,et al.  Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells , 2016, Nature.

[149]  Morteza Mahmoudi,et al.  Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. , 2016, Nature nanotechnology.

[150]  Atique U. Ahmed,et al.  CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. , 2016, Cancer research.

[151]  Philippe Foubert,et al.  PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.

[152]  T. Handel,et al.  Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices , 2016, Proceedings of the National Academy of Sciences.

[153]  M. Nahrendorf,et al.  Abandoning M1/M2 for a Network Model of Macrophage Function. , 2016, Circulation research.

[154]  C. Ries,et al.  Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity , 2016, Nature Cell Biology.

[155]  M. Rantalainen,et al.  Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. , 2016, Cell reports.

[156]  I. Weissman,et al.  First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  Kathryn J Fowler,et al.  Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. , 2016, The Lancet. Oncology.

[158]  K. Garcia,et al.  Durable antitumor responses to CD47 blockade require adaptive immune stimulation , 2016, Proceedings of the National Academy of Sciences.

[159]  Jennie W. Taylor,et al.  Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival , 2016, Proceedings of the National Academy of Sciences.

[160]  Y. Gilad,et al.  Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages. , 2016, Cancer research.

[161]  N. Gül,et al.  Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer. , 2015, Cancer research.

[162]  E. Pietsch,et al.  Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies , 2015, Blood Cancer Journal.

[163]  S. Scala.  Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment , 2015, Clinical Cancer Research.

[164]  P. Allavena,et al.  Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy , 2015, Gut.

[165]  Weina Li,et al.  Specific cellular immune response elicited by the necrotic tumor cell-stimulated macrophages. , 2015, International immunopharmacology.

[166]  J. Pollard,et al.  CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages , 2015, The Journal of experimental medicine.

[167]  D. Gao,et al.  microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma , 2015, Journal of Hematology & Oncology.

[168]  C. Watson,et al.  Anti-CCL2: building a reservoir or opening the floodgates to metastasis? , 2015, Breast Cancer Research.

[169]  Brian Ruffell,et al.  Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.

[170]  Steffen Jung,et al.  Macrophages: development and tissue specialization. , 2015, Annual review of immunology.

[171]  P. Allavena,et al.  The interaction of anticancer therapies with tumor-associated macrophages , 2015, The Journal of experimental medicine.

[172]  G. Natoli,et al.  Macrophages and cancer: from mechanisms to therapeutic implications. , 2015, Trends in immunology.

[173]  M. Detmar,et al.  Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer , 2015, Scientific Reports.

[174]  I. Weissman,et al.  Macrophages are critical effectors of antibody therapies for cancer , 2015, mAbs.

[175]  Ioannis Xenarios,et al.  Angiogenic Activity of Breast Cancer Patients’ Monocytes Reverted by Combined Use of Systems Modeling and Experimental Approaches , 2015, PLoS Comput. Biol..

[176]  T. Daemen,et al.  Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy , 2015, Oncoimmunology.

[177]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[178]  Diana Boraschi,et al.  From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation , 2014, Front. Immunol..

[179]  M. Ebsen,et al.  Tumor‐associated macrophages exhibit pro‐ and anti‐inflammatory properties by which they impact on pancreatic tumorigenesis , 2014, International journal of cancer.

[180]  E. Song,et al.  Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages , 2014, Oncoimmunology.

[181]  H. Yao,et al.  A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. , 2014, Cancer cell.

[182]  H. Atmaca,et al.  Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells , 2014, European Cytokine Network.

[183]  Tom C. Freeman,et al.  Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation , 2014, Immunity.

[184]  P. Kubes,et al.  Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. , 2014, The Journal of clinical investigation.

[185]  Jun Li,et al.  Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. , 2014, Cellular signalling.

[186]  M. Czyz,et al.  The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes. , 2014, Immunobiology.

[187]  R. Weichselbaum,et al.  Radiation as an immune modulator. , 2013, Seminars in radiation oncology.

[188]  P. Taylor,et al.  Tissue-resident macrophages , 2013, Nature Immunology.

[189]  E. Bozkurt,et al.  A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells. , 2013, Toxicology letters.

[190]  Barbara L. Smith,et al.  Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  C. Napoli,et al.  CXCR4 inhibitors: tumor vasculature and therapeutic challenges. , 2012, Recent patents on anti-cancer drug discovery.

[192]  L. Naldini,et al.  Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis , 2011, Clinical Cancer Research.

[193]  Wei Li,et al.  Tubby and tubby‐like protein 1 are new MerTK ligands for phagocytosis , 2010, The EMBO journal.

[194]  I. Weissman,et al.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy , 2017, Nature Immunology.

[195]  Naveid A Ali,et al.  Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. , 2015, Cancer discovery.

[196]  T. O’Toole,et al.  Myeloid cells as effector cells for monoclonal antibody therapy of cancer. , 2014, Methods.

[197]  P. Bonaldo,et al.  Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. , 2013, International review of cell and molecular biology.